An uncommon t(9;11)(p24; q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia

被引:1
|
作者
Lovatel, Viviane Lamim [1 ,6 ]
de Souza, Daiane Correa [1 ]
Alvarenga, Tatiana Fonseca [2 ,3 ]
Capela de Matos, Roberto R. [1 ,6 ]
Diniz, Claudia [1 ]
Schramm, Marcia Trindade [4 ]
Llerena Junior, Juan Clinton [5 ]
Macedo Silva, Maria Luiza [1 ,6 ]
Abdelhay, Eliana [1 ,6 ]
Fernandez, Teresa de Souza [1 ,6 ]
机构
[1] Natl Canc Inst INCA, Bone Marrow Transplatat Ctr CEMO, Rio De Janeiro, Brazil
[2] Univ Estado Rio De Janeiro, Natl Canc Inst INCA, Pathol Dept, Rio De Janeiro, Brazil
[3] Univ Estado Rio De Janeiro, Postgrad Program Med Sci, Rio De Janeiro, Brazil
[4] Natl Canc Inst INCA, Hematol Dept, Rio De Janeiro, Brazil
[5] Fundacao Oswaldo Cruz, Fernandes Figueira Natl Inst, Med Genet Dept, Rio De Janeiro, RJ, Brazil
[6] Natl Canc Inst Jose Alencar de Gomes da Silva INC, Postgrad Program Oncol, Rio De Janeiro, Brazil
关键词
Myelodysplastic syndrome; Acute myeloid leukemia; Fanconi anemia; Classical cytogenetics; FISH; T(9; 11); ATM; KMT2A; RISK;
D O I
10.1186/s13039-018-0389-x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Myelodysplastic syndrome (MDS) is rare in the pediatric age group and it may be associated with inheritable bone marrow failure (BMF) such as Fanconi anemia (FA). FA is a rare multi-system genetic disorder, characterized by congenital malformations and progressive BMF. Patients with FA usually present chromosomal aberrations when evolving to MDS or acute myeloid leukemia (AML). Thus, the cytogenetic studies in the bone marrow (BM) of these patients have an important role in the therapeutic decision, mainly in the indication for hematopoietic stem cell transplantation (HSCT). The most frequent chromosomal alterations in the BM of FA patients are gains of the chromosomal regions 1q and 3q, and partial or complete loss of chromosome 7. However, the significance and the predictive value of such clonal alterations, with respect to malignant progress, are not fully understood and data from molecular cytogenetic studies are very limited. Case presentation: A five-year-old boy presented recurrent infections and persistent anemia. The BM biopsy revealed hypocellularity. G-banding was performed on BM cells and showed a normal karyotype. The physical examination showed to be characteristic of FA, being the diagnosis confirmed by DEB test. Five years later, even with supportive treatment, the patient presented severe hypocellularity and BM evolution revealing megakaryocyte dysplasia, intense dyserythropoiesis, and 11% myeloblasts. G-banded analysis showed an abnormal karyotype involving a der(9) t(9; 11)(p24; q? 22). The FISH analysis showed the monoallelic loss of ATM and KMT2A genes. At this moment the diagnosis was MDS, refractory anemia with excess of blasts (RAEB). Allogeneic HSCT was indicated early in the diagnosis, but no donor was found. Decitabine treatment was initiated and well tolerated, although progression to AML occurred 3 months later. Chemotherapy induction was initiated, but there was no response. The patient died due to disease progression and infection complications. Conclusions: Molecular cytogenetic analysis showed a yet unreported der(9) t(9; 11)(p24; q? 22), der(11) t(9; 11)(p24; q? 22) during the evolution from FA to MDS/AML. The FISH technique was important allowing the identification at the molecular level of the monoallelic deletion involving the KMT2A and ATM genes. Our results suggest that this chromosomal alteration conferred a poor prognosis, being associated with a rapid leukemic transformation and a poor treatment response.
引用
收藏
页数:6
相关论文
共 6 条
  • [1] An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia
    Viviane Lamim Lovatel
    Daiane Corrêa de Souza
    Tatiana Fonseca Alvarenga
    Roberto R. Capela de Matos
    Claudia Diniz
    Marcia Trindade Schramm
    Juan Clinton Llerena Júnior
    Maria Luiza Macedo Silva
    Eliana Abdelhay
    Teresa de Souza Fernandez
    Molecular Cytogenetics, 11
  • [2] A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia
    Cirmena, Gabriella
    Aliano, Stefania
    Fugazza, Giuseppina
    Bruzzone, Roberto
    Garuti, Anna
    Bocciardi, Renata
    Bacigalupo, Andrea
    Ravazzolo, Roberto
    Ballestrero, Alberto
    Sessarego, Mario
    CANCER GENETICS AND CYTOGENETICS, 2008, 183 (02) : 105 - 108
  • [3] Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)( p21;q23)/KMT2A-MLLT3
    Panagopoulos, Ioannis
    Andersen, Kristin
    Eilert-Olsen, Martine
    Zeller, Bernward
    Munthe-Kaas, Monica Cheng
    Buechner, Jochen
    Osnes, Liv T. N.
    Micci, Francesca
    Heim, Sverre
    CANCER GENOMICS & PROTEOMICS, 2021, 18 (01) : 67 - 81
  • [4] Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia
    Tirado, Carlos A.
    Chen, Weina
    Huang, Lily Jun-shen
    Laborde, Carrie
    Hiemenz, Matthew C.
    Valdez, Federico
    Ho, Kevin
    Winick, Naomi
    Lou, Zhenjun
    Koduru, Prasad
    LEUKEMIA RESEARCH, 2010, 34 (12) : 1674 - 1676
  • [5] PAN3-PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia
    Panagopoulos, Ioannis
    Gorunova, Ludmila
    Andersen, Hege Kilen
    Bergrem, Astrid
    Dahm, Anders
    Andersen, Kristin
    Micci, Francesca
    Heim, Sverre
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [6] PAN3–PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia
    Ioannis Panagopoulos
    Ludmila Gorunova
    Hege Kilen Andersen
    Astrid Bergrem
    Anders Dahm
    Kristin Andersen
    Francesca Micci
    Sverre Heim
    Experimental Hematology & Oncology, 7